Danaher (DHR) shares fell more than 4% in premarket trading on Wednesday after the life sciences giant missed Street forecasts with its Q3 2026 revenue, as the company undergoes a leadership transition. The Washington, DC-based firm reported $6. 55B in revenue for the quarter, with ~9% YoY growth, yet missed the consensus by $10M as its diagnostic and life sciences segments failed to offset weakness in its biotech segment. 85B projected by analysts, respectively, while its biotech unit added $1. 80B compared with $1. CEO Julie Sawyer Montgomery, who took over the company’s leadership on Oct. 7, expressed confidence in the company’s performance and future opportunities.
Despite the revenue shortfall, the company reported strong earnings and cash flow, with CEO Montgomery highlighting improving trends across end markets. The stock drop came despite the company’s improved financial performance and guidance for 2026. The market reaction highlights concerns about the impact of the leadership transition on the company’s performance and future prospects.
The company’s strong earnings and guidance suggest that the underlying business is performing well, but the market remains cautious about the transition period and its effects on the company’s growth trajectory.